Effect of p16 Status on Survival Outcomes in Sinonasal Squamous Cell Carcinoma

Ann Otol Rhinol Laryngol. 2023 Aug;132(8):917-925. doi: 10.1177/00034894221121401. Epub 2022 Aug 29.

Abstract

Objective: Evaluate the effect of p16 status on disease-free survival (DFS) and overall survival (OS) in patients with sinonasal squamous cell carcinoma (SCC) undergoing treatment with curative intent; and to assess how p16 status may affect patterns of recurrence.

Study design: Retrospective cohort study.

Setting: Tertiary medical center.

Methods: Patients with sinonasal SCC treated with curative intent from 2012 to 2018 were identified. Independent variable of interest was p16 status, which was assessed using immunohistochemistry (IHC) with a 70% staining cutoff for positivity. Kaplan Meier survival curve was plotted to assess correlation between p16 status and DFS and OS. Association between recurrence patterns and p16 status was conducted using chi square and fisher's exact tests. Multivariable Cox proportional hazard analysis was conducted to assess association between independent variables and DFS.

Results: Fifty patients with sinonasal SCC met inclusion criteria. Patients were p16 positive in 28/50 (56%) of cases. Kaplan Meier survival curve revealed no statistically significant association between p16 status and DFS or OS survival (P = .780, P = .474). There was no difference in recurrence patterns in patients with p16 positive versus negative tumors.

Conclusion: p16 status did not have prognostic value on DFS and OS in our cohort of patients with sinonasal SCC undergoing treatment with curative intent. There was no difference in recurrence patterns between the 2 populations. Based on the results of this study, p16 status should not impact counseling of patients as it relates to their prognosis from SNM.

Keywords: human papilloma virus; p16; sinonasal malignancy; squamous cell carcinoma; survival.

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Cyclin-Dependent Kinase Inhibitor p16 / analysis
  • Disease-Free Survival
  • Humans
  • Paranasal Sinus Neoplasms* / therapy
  • Prognosis
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck

Substances

  • Cyclin-Dependent Kinase Inhibitor p16